Marco High-Cost Drugs integrates an extensive database of high-cost medications for Thyroid Cancer, enabling hospitals, payers and regulatory bodies to access updated information on approved indications, efficacy evidence, coverage criteria and therapeutic alternatives. The system supports evidence-based access and reimbursement decisions.
Some answers to questions we often receive
Marco High-Cost Drugs includes all high-cost oncology medications available for Thyroid Cancer: lenvatinib, sorafenib, cabozantinib, vandetanib, selpercatinib and dabrafenib in BRAF+ anaplastic, with their FDA and EMA approved indications, eligibility criteria (biomarkers, treatment line, performance status) and the evidence level supporting each indication per NCCN and ESMO guidelines.
Yes. Marco High-Cost Drugs includes for each Thyroid Cancer medication comparable therapeutic alternatives with efficacy comparisons (OS, PFS), toxicity profile and relative cost. This information supports therapeutic substitution decisions, vendor negotiations and institutional appropriate-use guideline design.
Marco High-Cost Drugs provides centralized procurement bodies and health ministries with the information needed for high-cost drug procurement in Thyroid Cancer: consolidated indications, estimated use volumes, available alternatives and comparative efficacy data supporting procurement justification and lab negotiations.
Marco High-Cost Drugs provides payers with evidence-based authorization criteria for high-cost medications in Thyroid Cancer, automatically verifying the consistency between the physician's request and approved indications. This reduces review times, standardizes decisions and minimizes off-label treatment authorizations.
The Marco team continuously monitors FDA, EMA and regional regulatory agency approvals for Thyroid Cancer. Every new approval, indication extension or label change is incorporated with precise indications, use criteria and clinical trial evidence that supported the approval.
Yes. Marco High-Cost Drugs includes approved biosimilars available for each biologic medication in Thyroid Cancer, with the comparability studies supporting interchangeability, approved indications for each biosimilar and local regulatory considerations for their use in hospitals and by payers.
The high cost of lenvatinib and RET inhibitors generates rejections from payers unaware of updated indication criteria.